Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDs

被引：5
|
作者：
Paydas, Semra [1 ]
机构：
[1] Cukurova Univ, Fac Med, Dept Oncol, Adana, Turkey
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 08期
关键词：
D O I：
10.1080/10428190802187155
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1644 / 1645
页数：2
相关论文
共 50 条
  • [31] Potential use of new generation of immunomodulatory imide drugs (IMiDs) against IMiDs resistant multiple myeloma
    Matsuda, Keishi
    Kariya, Ryusho
    Okada, Seiji
    CANCER SCIENCE, 2024, 115 : 2129 - 2129
  • [32] A clinical audit of venous thromboprophylaxis in multiple myeloma
    Lyengar, S.
    Ayto, R.
    Wechalekar, A.
    Dwanga, F.
    Mehta, A. B.
    Hughes, D. A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 12 - 12
  • [33] Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis
    Leleu, Xavier
    Iacobelli, Simona
    Barrois, Alain
    Pelle, Benjamin
    Clark, Liz
    Boyle, Eileen
    Moreau, Philippe
    Dib, Mamoun
    Caillot, Denis
    Niederwieser, Dietger
    Masszi, Tamas
    Fontan, Jean
    Doyen, Chantal
    Hajek, Roman
    Onida, Francesco
    Ludwig, Heinz
    de Witte, Theo M.
    Gahrton, Gosta
    Morris, Curly T. C. M.
    Garderet, Laurent
    BLOOD, 2011, 118 (21) : 1434 - 1434
  • [34] Aspirin May be Inadequate Thromboprophylaxis in Multiple Myeloma
    Sanfilippo, Kristen M.
    Luo, Suhong
    Carson, Kenneth R.
    Gage, Brian F.
    BLOOD, 2017, 130
  • [35] Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma
    Zanwar, Saurabh
    Ho, Matthew
    Kapoor, Prashant
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Dingli, David
    Kourelis, Taxiarchis
    Fonder, Amie
    Hobbs, Miriam
    Hwa, Yi
    Gonsalves, Wilson
    Warsame, Rahma
    Muchtar, Eli
    Leung, Nelson
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji
    LEUKEMIA, 2022, 36 (03) : 873 - 876
  • [36] Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma
    Zanwar, Saurabh
    Ho, Matthew
    Kapoor, Prashant
    Dispenzieri, Angela
    Gertz, Morie A.
    Lacy, Martha Q.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Dingli, David
    Kourelis, Taxiarchis
    Fonder, Amie
    Hwa, Yi L.
    Hobbs, Miriam A.
    Gonsalves, Wilson I.
    Warsame, Rahma M.
    Muchtar, Eli
    Leung, Nelson
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji
    BLOOD, 2021, 138
  • [37] Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma
    Saurabh Zanwar
    Matthew Ho
    Prashant Kapoor
    Angela Dispenzieri
    Martha Q. Lacy
    Morie A. Gertz
    Francis K. Buadi
    Suzanne R. Hayman
    David Dingli
    Taxiarchis Kourelis
    Amie Fonder
    Miriam Hobbs
    Yi Hwa
    Wilson Gonsalves
    Rahma Warsame
    Eli Muchtar
    Nelson Leung
    Robert A. Kyle
    S. Vincent Rajkumar
    Shaji Kumar
    Leukemia, 2022, 36 : 873 - 876
  • [38] Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis
    Adrianzen-Herrera, Diego
    Giorgio, Katherine
    Walker, Rob F.
    Sparks, Andrew D.
    Gergi, Mansour
    Zakai, Neil A.
    Lutsey, Pamela L.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (04)
  • [39] Thromboprophylaxis for prevention of venous thromboembolism in patients with multiple myeloma - a systematic review and metaanalysis
    Suryanarayan, D.
    Zepeda, V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 : 79 - 80
  • [40] A Survey of UK Myeloma treating centres on thrombosis risk assessment and thromboprophylaxis practice in patients with Multiple Myeloma
    Oliver, R.
    Bygrave, C.
    Cook, G.
    Jackson, G.
    Bradbury, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 130 - 131
12345